Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
Archive, CME credit no longer available
Release Date: September 19, 2006
Expiration Date: September 19, 2007
This activity consists of audio and visual recording of 17 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Design antiretroviral treatment regimens that consider
- New developments in the study of the pathogenesis of HIV
- HIV super infection
- Current information on initiating antiretroviral therapy
- Management of complicated antiretroviral failure and drug resistance
- The role of HIV resistance testing and nuances in interpretation of the results
- The potential future role of new investigational antiretrovirals
- Long-term metabolic complications, including lipid abnormalities, cardiovascular risk, and insulin and diabetes
- List the major issues regarding the management of specific patient populations with HIV infection, including women, adolescents, and methamphetamine users
- Describe the incidence, diagnosis, and management of specific coinfections commonly seen in HIV-infected patients, including hepatitis B virus, and syphilis and other sexually transmitted diseases
- Implement strategies for addressing HIV primary care and renal toxicity, taking into account increasing rates of comorbidity and survival in HIV patients
- Describe new methods for introducing changes in patient behavior and prevention for positives
- Discuss new developments in HIV testing and their potential impact on medical practice and the healthcare system
- Identify current issues in occupational and non-occupational post-exposure prophylaxis
CME Credit
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of 13.5
AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity. Other clinicians will receive a certificate of attendance for participating in this activity.
Intended Audience for CME Credit
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Co-Chairs
Laura W. Cheever, MD
Chief Medical Officer
Deputy Associate Administrator
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Michael S. Saag, MD
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Donna E. Sweet, MD
Professor of Medicine
University of Kansas School of Medicine
Principal Investigator/Director
The Kansas AIDS Education and Training Center
Wichita, Kansas
Program Planning Committee
Laura W. Cheever, MD
Chief Medical Officer
Deputy Associate Administrator
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Lois Eldred, DrPH, MPH
Acting Director
Global HIV/AIDS Program
Health Resources and Services Administration
Rockville, Maryland
Donna M. Jacobsen
President and Founding Executive Director
International AIDS Society–USA
San Francisco, California
José R. Morales, MD
Director
Division of Community Based Programs
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Michael S. Saag, MD
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Donna E. Sweet, MD
Professor of Medicine
University of Kansas School of Medicine
Principal Investigator/Director
The Kansas AIDS Education and Training Center
Wichita, Kansas
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)
Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)
Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)
Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)
Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)
Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)
Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)
Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Adeyemi has received research and grant support from Abbott and GlaxoSmithKline. She has served as a scientific advisor to Idenix, Roche, and Tibotec. She also has received honoraria for lectures from Abbott.
Dr Celum has received grants and research support and has received honoraria for lectures from GlaxoSmithKline.
Dr Cheever has no relevant financial affiliations to disclose.
Dr Cohen has served as a scientific advisor for GlaxoSmithKline.
Dr Eldred has no relevant financial affiliations to disclose.
Dr Eron has received grants and research support from Merck and Panacos. He has also served as a consultant to or is on the speakers bureau of Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Trimeris, Virco, and Monogram Biosciences.
Dr Fine has received honoraria for lectures from Amgen and GlaxoSmithKline. He served as a consultant to GlaxoSmithKline.
Dr Futterman has no relevant financial affiliations to disclose.
Dr Grant has received research and grant support from Abbott and Bayer. He has served as a scientific advisor or consultant to Bayer and Monogram Biosciences.
Dr Gulick has received research grant support from Abbott, Boehringer Ingelheim, Merck, Pfizer, Serono, Schering, and Tibotec. He has also served as a scientific advisor or consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, and Tibotec. He has received speaker honoraria from Gilead and Monogram Biosciences.
Ms Jacobsen has no relevant financial affiliations to disclose.
Dr Janssen has no relevant financial affiliations to disclose.
Dr Justice has no relevant financial affiliations to disclose.
Dr Morales has no relevant financial affiliations to disclose.
Dr Saag has received grants and research support from Gilead, GlaxoSmithKline, Panacos, Pfizer/Agouron, Roche, Serono, and Tibotec. He has served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer/Agouron, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex.
Dr Shoptaw has no relevant financial affiliations to disclose.
Dr Siliciano has no relevant financial affiliations to disclose.
Dr Spach has received honoraria for lectures from Merck and GlaxoSmithKline.
Dr Sweet is on the speakers’ bureau of Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Pfizer, Roche, and Wyeth.
Dr Thio has received honoraria for lectures from Bristol-Myers Squibb and has received honoraria for enduring materials from Bristol-Myers Squibb.
Ms Wilson has no relevant financial affiliations to disclose.
Dr Zorrilla has received grants and research support from Bristol-Myers Squibb, Pfizer, Roche, and Tibotec.
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, the AIDS Education and Training Centers National Resource Center, and the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2007@iasusa.org
